Ardelyx, Inc. Expected to Release Data in First Half of 2017 from Onset-of-Action Study Evaluating the Effect of RDX7675 on the Rate of Blood Potassium Lowering, Along with Safety and Efficacy, in Patients with Hyperkalemia - Discontinued

Source Link:

http://www.prnewswire.com/news-releases/ardelyx-announces-initiation-of-two-clinical-trials-for-rdx7675-for-treatment-of-hyperkalemia-300384449.html